Newron Pharmaceuticals (NWPHF) Short Interest Ratio & Short Volume

Short interest is the volume of Newron Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of March 31st, traders have sold 79,100 shares of NWPHF short. 0.44% of Newron Pharmaceuticals' shares are currently sold short. Learn More on Newron Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.44% of Newron Pharmaceuticals' floating shares are currently sold short.

Newron Pharmaceuticals saw a decrease in short interest in March. As of March 31st, there was short interest totaling 79,100 shares, a decrease of 1.6% from the previous total of 80,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.44% of Newron Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Newron Pharmaceuticals: Nuvation Bio Inc. (14.16%), Rocket Pharmaceuticals, Inc. (19.09%), Evolus, Inc. (12.03%), Xeris Biopharma Holdings, Inc. (11.98%), ArriVent BioPharma, Inc. (20.95%), Dianthus Therapeutics, Inc. (23.78%), Pharming Group (0.50%), Arvinas, Inc. (9.80%), Trevi Therapeutics, Inc. (9.46%), Arbutus Biopharma Co. (5.41%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks.

Short selling NWPHF is an investing strategy that aims to generate trading profit from Newron Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Newron Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NWPHF, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NWPHF, twice per month. The most recent reporting period available is March, 31 2025.